Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence

Transplantation

Volumn 97, Issue 8, 2014, Pages S7-S10

  Chan, See Ching ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Recurrence; Small for size liver graft

Indexed keywords

ALPHA FETOPROTEIN;

ARTICLE; CADAVER DONOR; CANCER PROGNOSIS; CANCER STAGING; COLD ISCHEMIA; DISEASE FREE SURVIVAL; GRAFT SIZE; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER RESECTION; LIVER TRANSPLANTATION; LIVING DONOR; OVERALL SURVIVAL; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; TUMOR GROWTH; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; ANIMAL; DONOR SELECTION; HOSPITAL ADMISSION; LIVER REGENERATION; LIVER TUMOR; METHODOLOGY; MORTALITY; PATHOLOGY; REVIEW; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COLD ISCHEMIA; DISEASE-FREE SURVIVAL; DONOR SELECTION; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVING DONORS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 85047288774     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000446278.43804.f9     Document Type: Article

References (32)

1. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693.
2. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33: 1394.
3. de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist 2007;12: 1321.
4. Lo CM. Deceased donation in Asia: challenges and opportunities. Liver Transpl 2012; 8(Suppl 2): S5.
5. Chan SC, Fan ST, Lo CM, et al. A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg 2008;248:411.
6. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007;7: 1601.
7. Picardo A, Karpoff HM, Ng B, et al. Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 1998;124:57.
8. Yang ZF, Poon RT, Luo Y, et al. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol 2004;173: 2507.
9. Man K, Lo CM, Xiao JW, et al. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008;247: 1049.
10. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004;5:836.
11. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91.
12. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7.
13. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepato-cellular carcinoma. Br J Surg 2007;94:78-86.
14. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35.
15. Barr ML, Belghiti J, Villamil FG, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006;81: 1373.
16. Washburn K, Edwards E, Harper A, et al. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010;10: 1643.
17. Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant 2012;12: 2997.
18. Hwang S, Lee SG, Ahn CS, et al. Small-sized liver graft does not increase the risk of hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc 2007;39: 1526.
19. Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012;18:315.
20. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13: 1637.
21. Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011;53: 1570.
22. Liang W, Wu L, Ling X, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18: 1226.
23. Grant RC, Sandhu L, Dixon PR, et al. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant 2013;27:140.
24. Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009;249:118.
25. Chu KK, Chan SC, Fan ST, et al. Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy. Hepatobiliary Pancreat Dis Int 2012;11:612.
26. Lu DS, Siripongsakun S, Lee JK, et al. Complete tumor encapsulation on MRI: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma. Liver Transpl 2013;19:283.
27. DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166.
28. Kornberg A, Freesmeyer M, Barthel E, et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592.
29. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682.
30. Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531.
31. Choi GH, Park JY, Hwang HK, et al. Predictive factors for longterm survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma. Liver Int 2011;31:485.
32. Chan SC, Fan ST, Chok KS, et al. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int 2011 Oct 21. [Epub ahead of print].